Drug Trial Radar · NCT02296138
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Last checked: Nov 19, 2026Latest source record: Jun 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,903
Actual
Start
Jan 13, 2015
Primary completion
Mar 8, 2017
Study completion Mar 29, 2017
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
olodaterolDrug
fixed dose combination
tiotropiumDrug
fixed dose combination
tiotropiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period.Time frame: From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days
Locations
818 sites in 51 countries. Site status is shown where the registry gives one.
1237.19.10039 Boehringer Ingelheim Investigational Site
Andalusia, Alabama
1237.19.10009 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1237.19.10077 Boehringer Ingelheim Investigational Site
Florence, Alabama
1237.19.10115 Boehringer Ingelheim Investigational Site
Jasper, Alabama
1237.19.10069 Boehringer Ingelheim Investigational Site
Flagstaff, Arizona
1237.19.10085 Boehringer Ingelheim Investigational Site
Peoria, Arizona
1237.19.10110 Boehringer Ingelheim Investigational Site
Lincoln, California
1237.19.10118 Boehringer Ingelheim Investigational Site
Los Angeles, California
1237.19.10074 Boehringer Ingelheim Investigational Site
Poway, California
1237.19.10157 Boehringer Ingelheim Investigational Site
Lafayette, Colorado
1237.19.10142 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
1237.19.10133 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
1237.19.10093 Boehringer Ingelheim Investigational Site
Stamford, Connecticut
1237.19.10029 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1237.19.10106 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1237.19.10020 Boehringer Ingelheim Investigational Site
Orlando, Florida
1237.19.10000 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
1237.19.10135 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
1237.19.10145 Boehringer Ingelheim Investigational Site
Tamarac, Florida
1237.19.10066 Boehringer Ingelheim Investigational Site
Tampa, Florida
1237.19.10032 Boehringer Ingelheim Investigational Site
Winter Park, Florida
1237.19.10080 Boehringer Ingelheim Investigational Site
Duluth, Georgia
1237.19.10011 Boehringer Ingelheim Investigational Site
Gainesville, Georgia
1237.19.10112 Boehringer Ingelheim Investigational Site
Lawrenceville, Georgia
1237.19.10037 Boehringer Ingelheim Investigational Site
Eagle, Idaho
1237.19.10130 Boehringer Ingelheim Investigational Site
O'Fallon, Illinois
1237.19.10065 Boehringer Ingelheim Investigational Site
River Forest, Illinois
1237.19.10122 Boehringer Ingelheim Investigational Site
Muncie, Indiana
1237.19.10063 Boehringer Ingelheim Investigational Site
Topeka, Kansas
1237.19.10048 Boehringer Ingelheim Investigational Site
Bowling Green, Kentucky
1237.19.10108 Boehringer Ingelheim Investigational Site
Fort Mitchell, Kentucky
1237.19.10109 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana
1237.19.10095 Boehringer Ingelheim Investigational Site
Opelousas, Louisiana
1237.19.10113 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
1237.19.10139 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
1237.19.10117 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1237.19.10083 Boehringer Ingelheim Investigational Site
Columbia, Maryland
1237.19.10072 Boehringer Ingelheim Investigational Site
Hollywood, Maryland
1237.19.10027 Boehringer Ingelheim Investigational Site
Fall River, Massachusetts
1237.19.10138 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts
Showing 40 of 818 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.